Proteomics 2008, 8: 2012–2023.CrossRefPubMed 17. Arbuthnot P, Kew M: Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 2001, 82: 77–100.CrossRefPubMed 18. Ma NF, Lau SH, Hu L, Xie D, Wu J, Yang J, Wang Y, Wu MC, Fung J, Bai X, et al.: COOH-terminal Metabolism inhibitor truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res 2008, 14: 5061–5068.CrossRefPubMed 19.
Benn J, Schneider RJ: Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci USA 1995, 92: 11215–11219.CrossRefPubMed 20. Feitelson MA, Duan LX: Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol 1997, 150: 1141–1157.PubMed 21. Liang X, Du J, Liu Y,
Cui M, Ma C, Han L, Qu Z, Zhang Z, Sun Z, Zhang L, et al.: The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced Barasertib apoptosis through ERK2. Apoptosis 2007, 12: 1827–1836.CrossRefPubMed 22. Wang HC, Huang W, Lai MD, Su IJ: Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer ITF2357 Sci 2006, 97: 683–688.CrossRefPubMed 23. Wang HC, Chang WT, Chang WW, Wu HC, Huang W, Lei HY, Lai MD, Fausto N, Su IJ: Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology 2005, 41: 761–770.CrossRefPubMed 24. Lee HC, Kim M, Wands JR: Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 2006, 11: 1901–1915.CrossRefPubMed 25. Roberts LR, Gores GJ: Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis PIK3C2G 2005, 25: 212–225.CrossRefPubMed 26. Giles RH, van Es JH, Clevers H: Caught up in
a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1653: 1–24.PubMed 27. Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature 2005, 434: 843–850.CrossRefPubMed 28. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C: Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998, 95: 8847–8851.CrossRef 29. Bengochea A, de Souza MM, Lefrancois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P, et al.: Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 2008, 99: 143–150.CrossRefPubMed 30. Schmitt-Graeff A, Ertelt-Heitzmann V, Allgaier HP, Olschewski M, Nitschke R, Haxelmans S, Koelble K, Behrens J, Blum HE: Coordinated expression of cyclin D1 and LEF-1/TCF transcription factor is restricted to a subset of hepatocellular carcinoma. Liver Int 2005, 25: 839–847.CrossRefPubMed 31. Hovanes K, Li TW, Waterman ML: The human LEF-1 gene contains a promoter preferentially active in lymphocytes and encodes multiple isoforms derived from alternative splicing. Nucleic Acids Res 2000, 28: 1994–2003.CrossRefPubMed 32.